Health Care [ 8/12 ] | Biotechnology [ 38/75 ]
NASDAQ | Common Stock
Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.
The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody.
Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions.
The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; SanofiS. A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 11, 26 | 1.88 Increased by +11.24% | 1.86 Increased by +1.08% |
| Oct 30, 25 | 2.17 Increased by +19.89% | 2.09 Increased by +3.83% |
| Jul 30, 25 | 1.65 Increased by +161.90% | 1.50 Increased by +10.00% |
| May 5, 25 | 0.70 Increased by +66.67% | 1.09 Decreased by -35.78% |
| Feb 6, 25 | 1.69 Increased by +17.36% | 1.93 Decreased by -12.44% |
| Oct 30, 24 | 1.81 Increased by +120.73% | 1.82 Decreased by -0.55% |
| Aug 1, 24 | 0.63 Decreased by -33.68% | 1.05 Decreased by -40.00% |
| May 1, 24 | 0.42 Increased by +153.16% | 1.01 Decreased by -58.42% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 805.50 M Increased by +28.33% | 153.70 M Increased by +49.08% | Increased by +19.08% Increased by +16.17% |
| Sep 30, 25 | 794.90 M Increased by +27.78% | 209.50 M Increased by +61.40% | Increased by +26.36% Increased by +26.32% |
| Jun 30, 25 | 687.50 M Increased by +16.49% | 107.50 M Increased by +65.38% | Increased by +15.64% Increased by +41.98% |
| Mar 31, 25 | 572.60 M Increased by +11.12% | 7.90 M Decreased by -81.80% | Increased by +1.38% Decreased by -83.62% |
| Dec 31, 24 | 627.70 M Increased by +21.84% | 103.10 M Decreased by -30.20% | Increased by +16.43% Decreased by -42.71% |
| Sep 30, 24 | 622.10 M Increased by +24.72% | 129.80 M Increased by +56.20% | Increased by +20.86% Increased by +25.24% |
| Jun 30, 24 | 590.20 M Increased by +30.37% | 65.00 M Decreased by -31.94% | Increased by +11.01% Decreased by -47.79% |
| Mar 31, 24 | 515.30 M Increased by +22.57% | 43.40 M Increased by +156.66% | Increased by +8.42% Increased by +146.22% |